Kexing Biopharm's GB18 project received clearance of IND application from NMPA and FDA
SHENZHEN, China, May 29, 2025 /PRNewswire/ -- On May 26th, Kexing Biopharm (688136.SH) announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its independently developed...
SHEIN's Science-Based Net-Zero Target is Approved by SBTi
SINGAPORE, May 27, 2025 /PRNewswire/ -- As a global online fashion and lifestyle retailer, we have reached a milestone in our climate journey with the Science Based Targets initiative (SBTi) validating our net-zero science-based target by 2050 and...
RemeGen: Telitacicept for the Treatment of Generalized Myasthenia Gravis Approved in China
YANTAI, China, May 27, 2025 /PRNewswire/ -- On May 27, RemeGen Co., Ltd.(688331.SH / 09995.HK) announced that Telitacicept has officially been approved for marketing in China by the National Medical Products Administration (NMPA) for the treatment...
World's First -- XellSmart's Allogeneic iPSC-derived Regenerative Cell Therapy for Spinal Cord Injury Officially Approved by the U.S. FDA for a Registrational Phase I Clinical Trial
SUZHOU, China, May 26, 2025 /PRNewswire/ -- In May 2025, XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd. officially announced that XellSmart-developed off-the-shelf allogeneic iPSC-derived subtype-specific neural regenerative cell therapy...
Yunji Selects WWC, P.C. as its Independent Registered Public Accounting Firm
HANGZHOU, China, May 22, 2025 /PRNewswire/ -- Yunji Inc. ("Yunji" or the "Company") (NASDAQ: YJ), a leading membership-based social e-commerce platform, today announced that the Company's board of directors and the audit committee of the board...
Celltrion's YUFLYMA® (adalimumab-aaty) receives FDA interchangeability designation for all its approved dosage forms and strengths
YUFLYMA ® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira ® (adalimumab) biosimilar [1] Celltrion previously received interchangeability (IC) designation for YUFLYMA® (adalimumab-aaty) in prefilled...
JinkoSolar's EAGLE® Preserve Program Approved as the State of Washington's 1st Module Stewardship Program
CAMPBELL, Calif., May 19, 2025 /PRNewswire/ -- JinkoSolar Holding Co., Ltd. (the "Company," or "JinkoSolar") (NYSE: JKS), one of the largest and most innovative solar module manufacturers in the world, today announced that EAGLE® Preserve, its...
Xuanzhu Biopharm's Xuanyuening® (BireociclibTablets) Approved for Dual Indications, Bringing Innovative Breakthroughs to Breast Cancer Treatment
HONG KONG, May 16, 2025 /PRNewswire/ -- On May 15, 2025, the latest announcement released by the National Medical Products Administration attracted widespread attention in the oncology community and the pharmaceutical market. Bireociclib tablets...
Infineon gains approval of Science Based Targets initiative for ambitious CO2 emission reduction targets
Scope 1 and 2 targets meet highest SBTi standard for near-term reduction goals Infineon sets ambitious scope 3 target to further reduce emissions along the supply chain Active work with over one hundred suppliers to further reduce emissions MUNICH,...
Dupixent approved in Singapore as the first-ever biologic medicine for patients with COPD
Following recent approvals in the EU, US and China, the Singapore approval is based on two replicate phase 3 studies that showed Dupixent achieved significant reduction in exacerbations, and also showed improvements in lung function and...